pBG690 SARS-CoV-2 Nucleocapsid Protein Expression Plasmid
Highlights:
In response to the SARS-CoV-2/COVID-19 outbreak, the Geiss Lab produced a bacterial expression plasmid that encodes a bacterial codon-optimized fragment of the SARS-CoV-2 nucleocapsid protein. The SARS nucleocapsid protein was used as a diagnostic marker for SARS infection, and the recombinant SARS-CoV-2 nucleocapsid protein may be used as a similar diagnostic tool. To produce this plasmid, they synthesized a bacterial-codon optimized gene representing amino acids 133-416 of the SARS-CoV-2 nucleocapsid protein and cloned the sythentic gene into the pET28a T7 expression vector. The plasmid was sequence verified. They then developed a bacterial expression protocol that can produce monomeric nucleocapsid protein (as confirmed by mass spectroscopy) with greater than 95% purify. Purified nucleocapsid protein has been tested by collaborators for antigenicity in mice immunized against the recombinant protein as well as bats infected with SARS-CoV-2.
From the laboratory of Brian J. Geiss, PhD, Colorado State University.
Product Type: | Plasmid |
Name: | SARS-CoV-2 Nucleocapsid Protein Expression Plasmid |
Gene/insert name: | SARS-CoV-2 Nucleocapsid Protein (aa 133-416) |
Organism: | E.coli |
Antibiotic Resistance: | Kanamycin |
Fusion Tag(s): | C-term His |
Grow in E. coli at 37 C: | Yes |
Vector Backbone and Size: | pET28a, 5369bp |
High or low copy: | High |
Storage: | -20C |
Shipped: | Room temperature |
If you publish research with this product, please let us know so we can cite your paper.